MDWD News & Events

The Company reaffirms its revenue guidance of $24-26 million for 2026.

The Company reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028. Guidance assumes continued support from BARDA and the U.S. Department of War. The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval.

Reports Q4 revenue $1.867M, consensus $2.09M. "We entered 2026 with two strategic growth drivers," said Ofer Gonen, Chief Executive Officer of MediWound. "Our Phase III VALUE trial of EscharEx continues to progress as planned, with key clinical milestones, including interim assessment and enrollment completion, anticipated by year-end. In parallel, our expanded NexoBrid manufacturing facility is now operational, positioning us to support global demand following regulatory approvals. With these value-creating catalysts, a strong balance sheet, and an experienced team, MediWound is now well-positioned to advance into a new phase of scale and commercial readiness."